biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH
Theravance Biopharma Ireland
Theravance Biopharma Ireland Umited
Theravance Biopharma Ireland clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 901 Gateway Blvd., South San Francisco, CA 94080, US
- Founded
- 2014
- Employees
- 177
- Programs
- 57
- Drugs
- 18
- Patents
- 635
Theravance Biopharma Ireland projects
3 ClinicalTrials.gov programs sponsored by Theravance Biopharma Ireland.
Theravance Biopharma Ireland has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Revefenacin
Theravance Biopharma Ireland Umited
Chronic Obstructive Pulmonary Disease
1 trial -
Telavancin
Theravance Biopharma Ireland Umited
End-Stage Renal Disease
1 trial -
umeclidinium 62.5 µg and vilanterol 25 µg
Theravance Biopharma Ireland Umited
COPD (Chronic Obstructive Pulmonary Disease)
1 trial
Frequently asked questions
How many clinical projects does Theravance Biopharma Ireland have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.